← FDA ENFORCEMENT
D-0606-2025Class II
Boothwyn Pharmacy LLC
What this record is not
A recall record is reproduced as FDA published it, and the classification is FDA’s. SPEQ adds no interpretation, and a recall concerns the products and dates in the record — it is not a statement about a company’s other products or its current status.
Recalling firm
Boothwyn Pharmacy LLC
Product type
Drug
Status
Ongoing
Report date
2025-09-10
Distribution
U.S. Nationwide
Firm state
PA
Product quantity
642 vials
Initiated by
Voluntary: Firm initiated
SPEQ quality domain
Validation & QualificationReason for recall
Subpotent Drug
Product description
Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy
Code / lot info
03202025@5, 03202025@6, 03202025@7, 03202025@8 BUD 07/18/2025
Other recalls SPEQ maps to Validation & Qualification
2026-10-21Class IIZydus Pharmaceuticals (USA) Inc2026-10-21Class IIIMagellan Diagnostics, Inc.2026-10-21Class IIMicrogenics Corporation2026-10-14Class IICipla USA, Inc.
See all Validation & Qualification recalls →Data: U.S. FDA. Recall details are as reported by the FDA. The quality-domain mapping and severity are a SPEQ editorial interpretation of the recall reason, not an official FDA classification. Open the enforcement explorer →